cell models
Cell-based Analysis
additive printing of cell
based models
global market
predictive value of cell
market share
market data
market advantage
target market
Phase
human cell culture
scalable manufacturing of cell
based analysis systems
yearsâ€™ successful ACS cell-based business
commercial value
market-ready TRL9
competitive pricing of printed cell products
Post-project
high-value hepatotoxicity testing
commercial decisions
commercial partnership
high-end analysis available
wider integration of complex models
beta testing
cost-effective testing
financial impact
initial hepatotoxicity sales
healthcare products
financial planning
technology audit
sales extension
technology platform
business plan
ACS core skills
positive disruptive impact
multiple industry sectors
year post-launch
SE Asia
non-specialist users
JV companies
greater confidence
remote markets
client-reactive design
new drugs
materials
assay assembly
UK National Centre
services
iPSC-derived hepatocytes
prototypes
product range
third-party distributors
functional foods
Operational efficiencies
high-volume screening
Japan
Technical innovation
assays
existing operations
opinion leaders
CAGR
objective
budget
TRL7
Bn